Dose escalation of biologics in Crohn's disease: critical review of observational studies.

CONCLUSIONS: A substantial proportion of patients receiving ADA or IFX for Crohn's disease require dose escalation after a short period of time. PMID: 28537467 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research